© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - OPKO Health Acquires EirGen Pharma
Posted 28th May 2015

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

View Biography
Image

Paul Heffernan, Legal Adviser OPKO Health

OPKO Health, Inc. is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than 40 others around the world.

EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art high containment research and development, and manufacturing facility, is approved by the FDA, EMEA (European Health Authorities) and the PMDA (Japanese Health Authorities). High potency drugs such as those used for cancer chemotherapy are typically unsuitable for manufacture in normal multi-product facilities due to cross contamination risks.

To date, EirGen and its commercial partners have filed 10 product applications with the FDA and 5 each in Europe and Japan. EirGen has a strong research and development portfolio of over 20 niche, high barrier to entry drugs and, with access to additional capital that OPKO will provide, together with the benefits of Irish government programs to encourage research and development in Ireland, EirGen will rapidly expand its drug portfolio.

“EirGen Pharma is one of the leading developers and suppliers of high potency niche pharmaceutical products in the world,” said Phillip Frost, M.D. OPKO’s Chairman and CEO. “As FineTech, OPKO’s Israeli active pharmaceutical ingredient manufacturing subsidiary, is also focused on high potency drugs, an immediate business synergy is expected. EirGen also offers the significant benefit of potentially being able to manufacture OPKO’s current and future products in our own facilities, which we expect will result in even higher gross margins. The superb management, research and development, manufacturing and product distribution teams, along with state of the art facilities, together, will create an important, tax efficient base of operations for OPKO,” said Dr. Frost.

Categories: M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
Can You Pay to Have Your Credit Fixed?
Finance
06/12/2021Can You Pay to Have Your Credit Fixed?

Many companies claim they can "repair" or "fix" your credit. And yes, some of these types of services are scams. Moreover, you can do it yourself for free if you’re willing to put in the time and effort.

Read Full PostRead - Eye Icon
A Guide to Real Estate Investment Financing In Calgary’s Housing Market
News
04/09/2023A Guide to Real Estate Investment Financing In Calgary’s Housing Market

Dipping your toes into the Calgary housing market can be a profitable venture for both experienced investors and those just starting out. However, obtaining the right financing to turn your investment dreams into reality is crucial. In this article, we’l

Read Full PostRead - Eye Icon
Unrivalled Technical And Service Support
Leadership
09/02/2021Unrivalled Technical And Service Support

Water and energy solutions provider, Davis & Shirtliff, is a well-established brand in the East Africa region and is known for providing high quality products that are readily available and at competitive prices. Recently, we caught up with the firm’s He

Read Full PostRead - Eye Icon
Copyright Litigation- UK Trends
Leadership
20/11/2015Copyright Litigation- UK Trends

Ashfords is recognised nationally as a leading provider of legal and related professional services. Tom Phipps talks us through trends in the copyright litigation sector.

Read Full PostRead - Eye Icon
Canva Study Reveals Data Paradox: 78% Experience Data Anxiety Despite Training
News
04/06/2025Canva Study Reveals Data Paradox: 78% Experience Data Anxiety Despite Training

Global survey of more than 2,400 marketing and sales professionals reveals that while data dependency is growing, data competence lags, hindering productivity.

Read Full PostRead - Eye Icon
Financial Steps to Building a House
News
13/08/2021Financial Steps to Building a House

Building a home lets you personalize every aspect of where you live. You might also skip the renovations and repairs needed after purchasing an existing property, but the financial aspects of the planning and construction are less straightforward than buying a

Read Full PostRead - Eye Icon
Transforming the Pharmaceutical Landscape
Innovation
03/04/2018Transforming the Pharmaceutical Landscape

Sintetica S.A. is a pharmaceutical company delivering injectable anaesthetics and analgesics to patients worldwide through innovative science and excellence in development, production and marketing.

Read Full PostRead - Eye Icon
Furlough Scheme Extension – the Good, the Bad and the Ugly Cost
Finance
11/11/2020Furlough Scheme Extension – the Good, the Bad and the Ugly Cost

Shaw & Co, the Bristol-based specialist corporate finance advisory firm, has responded to the announcement made by Rishi Sunak, Chancellor of the Exchequer, on Thursday 5 November in the House of Commons announcing the extension of the UK Furlough Scheme.

Read Full PostRead - Eye Icon
CounselCorp Advises Aurobindo (Australia) Pty Ltd During Pharma Eris Pharma’s Acquisition
M&A
06/05/2015CounselCorp Advises Aurobindo (Australia) Pty Ltd During Pharma Eris Pharma’s Acquisition

In a move to focus the growth markets, the Hyderabad-based Aurobindo Pharma has sold off its step-down subsidiary in Australia, Aurobindo Pharma (Australia) Pty Ltd, to Eris Pharma Australia Pty Ltd.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow